Digest Network Come funziona
Network
/
Società
Gu
Non verificato

Guardant Health, Inc.

Di cosa scriviamo

BiotecnologiaIndustriaOncologiaSaluteSanità

107 comunicati stampa

Guarda tutti i comunicati
04/03/2026
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
03/03/2026
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
27/02/2026
Mercato azionario
Finanza
Sanità
Salute
Oncologia
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
19/02/2026
Biotecnologia
Attrezzature medico-sanitarie
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Mercato azionario
Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
03/02/2026
Tecnica
Associazioni/Professionisti
Software
Salute
Farmaceutica
Oncologia
Eventi
Guardant Health to Participate in Upcoming Investor Conferences
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
02/02/2026
Industria
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
29/01/2026
Biotecnologia
Farmaceutica
Salute
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
22/01/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Industria
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
19/01/2026
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0
11/01/2026
Biotecnologia
Salute
Oncologia
Attrezzature medico-sanitarie
Mercato azionario
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
Fonte
Guardant Health, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0